Checkpoint Inhibitor–TKI Combos Effective in RCC

Cancer Discovery - United States
doi 10.1158/2159-8290.cd-nb2019-024
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors

Unknown

Publisher

American Association for Cancer Research (AACR)

Related search

Neutrophil Lymphocyte Ratio and Duration of Prior Anti-Angiogenic Therapy as Biomarkers in Metastatic RCC Receiving Immune Checkpoint Inhibitor Therapy

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2017English

Kombinationstherapie Mit Checkpoint-Inhibitor

Uro-News
2017English

RCC: mTOR-Inhibitor Nach Gescheiterter Anti-Vegf-Therapie

Uro-News
2016English

Immune Checkpoint Inhibitor-Induced Fanconi Syndrome

Cureus
2020English

Webinar | Humanized Mouse Models in Checkpoint Inhibitor Development

Science
MultidisciplinaryPhilosophy of ScienceHistory
2017English

Immune Checkpoint Inhibitor Nephrotoxicity: Update 2020

Kidney360
2020English

PD-1 Checkpoint Inhibitor Associated Autoimmune Encephalitis

Case Reports in Oncology
Oncology
2017English

Rare Case of Tubulocystic RCC in Association With Papillary RCC

BMJ Case Reports
Medicine
2019English

A Case of Checkpoint Inhibitor-Induced Celiac Disease

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy